Abstract 6025
Background
Definitive treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) often incorporates concurrent chemoradiotherapy. Platinum agents have been the backbone of systemic therapy in combined modality approaches. However, the addition of cisplatin to radiotherapy (RT) results in a modest survival benefit and is associated with multiple acute and late toxicities. The study of alternative approaches is warranted. Nivolumab (nivo), a fully human anti-programmed cell death-1 (PD-1) monoclonal antibody (mAb), has demonstrated a survival advantage when compared with standard treatment in patients with platinum-refractory recurrent or metastatic SCCHN. Combination of nivo with the CTLA-4 directed mAb ipilimumab (ipi) has yielded improvements in antitumor activity in melanoma and is under investigation in multiple other solid tumor types including SCCHN. Similarly, the combination of RT and immunotherapy leads to synergistic effects in the laboratory and has promise in early phase clinical trials. This clinical trial combines immunotherapy and RT to build upon these observations.
Trial design
This is a single arm pilot trial that enrolls previously untreated patients with LA SCCHN who are candidates for curative intent, including stage IVA-B tumors of the oral cavity, oropharynx, hypopharynx, and larynx. HPV+ oropharyngeal tumors must be staged as T4, or N2c or N3 by AJCC 7th edition. Nivo and ipi are initiated 2 weeks prior to the beginning of RT. Nivo 3 mg/kg is administered every 2 weeks IV for a total of 17 doses and ipi 1 mg/kg is administered every 6 weeks for a total of 6 doses. RT (using IMRT) is prescribed as 2 Gy/fraction/day to a total dose of 70 Gy. The primary objective is the safety of the combination of nivo and ipi with RT with a focus on in-field toxicities (mucositis, dermatitis, edema, bleeding) with secondary endpoints of 1-year PFS, ORR, and OS. Exploratory correlative studies include tumor PD-L1 expression, tumor immune bias via the Th1/Th2 ratio, and exosome quantity and composition. The sample size is 24 patients following a two-stage design with 12 patients enrolled in the first stage and 12 more in the expansion cohort. Enrollment began in May 2017 and is ongoing.
Clinical trial identification
NCT03162731.
Legal entity responsible for the study
Thomas Jefferson University - Sidney Kimmel Cancer Center.
Funding
Bristol Myers Squibb.
Editorial Acknowledgement
Disclosure
J.M. Johnson: Pharmaceutical-sponsored investigator-initiated clinical trials funds: Bristol-Myers Squibb, AstraZeneca, Merck; Consultative services: Foundation Medicine. A. Luginbuhl, D. Cognetti, A. Argiris: Pharmaceutical sponsored investigator-initiated clinical trials funds: Bristol-Myers Squibb. J.M. Curry: Pharmaceutical-sponsored investigator-initiated clinical trials funds: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract